News >

Choueiri Highlights Advances and Next Steps in RCC

Brandon Scalea
Published: Tuesday, Dec 18, 2018

Toni K. Choueiri, MD

Toni K. Choueiri, MD
Over the last decade, there have been several breakthroughs made in the treatment of patients with renal cell carcinoma (RCC), as checkpoint inhibitors, targeted agents, and combination regimens received approvals from the FDA. Although the outlook is bright for patients, said Toni K. Choueiri, MD, refining what is now a complex treatment paradigm will be challenging.

For example, in the pivotal CheckMate-214 trial, the frontline combination of the checkpoint inhibitors nivolumab (Opdivo) and ipilimumab (Yervoy) demonstrated a clear survival advantage over sunitinib (Sutent) in patients with previously untreated RCC.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x